Difficulty: Medium
Average Score: 68%
Practice
Erythrocytic schizontocide antimalarial drugs are used as
Correct answer
D
Rationale
The correct answer is D) Both (a) and (b). Erythrocytic schizontocide antimalarial drugs are used for both suppressive prophylactic purposes and clinical curative treatment.
Explanation:
- Suppressive prophylactic: These drugs are used to prevent the development of malaria in individuals living in or traveling to endemic areas. By killing the erythrocytic form of the malaria parasite, they help prevent the clinical manifestation of the disease.
- Clinical curative: Erythrocytic schizontocides are also used to treat individuals who have already contracted malaria. By targeting the erythrocytic stage of the parasite, these drugs help eliminate the infection from the body.
Why the other options are incorrect:
- Option A) Suppressive prophylactic: This option is partially correct but does not encompass the full spectrum of uses for erythrocytic schizontocide antimalarial drugs.
- Option B) Clinical curative: This option is also partially correct but fails to acknowledge the prophylactic role of these drugs.
- Option C) Radical curative for P. Vivax: This option is incorrect as erythrocytic schizontocides primarily target the erythrocytic stage of the malaria parasite, not specifically for P. vivax.
Educational context:
Understanding the different uses of antimalarial drugs is crucial for healthcare professionals, especially those working in regions where malaria is prevalent. Recognizing the dual role of erythrocytic schizontocides in both prevention and treatment of malaria is essential for providing effective care to individuals at risk of or affected by malaria. This knowledge is also tested in exams like the NCLEX to ensure healthcare professionals are well-equipped to handle such scenarios in practice.
Explanation:
- Suppressive prophylactic: These drugs are used to prevent the development of malaria in individuals living in or traveling to endemic areas. By killing the erythrocytic form of the malaria parasite, they help prevent the clinical manifestation of the disease.
- Clinical curative: Erythrocytic schizontocides are also used to treat individuals who have already contracted malaria. By targeting the erythrocytic stage of the parasite, these drugs help eliminate the infection from the body.
Why the other options are incorrect:
- Option A) Suppressive prophylactic: This option is partially correct but does not encompass the full spectrum of uses for erythrocytic schizontocide antimalarial drugs.
- Option B) Clinical curative: This option is also partially correct but fails to acknowledge the prophylactic role of these drugs.
- Option C) Radical curative for P. Vivax: This option is incorrect as erythrocytic schizontocides primarily target the erythrocytic stage of the malaria parasite, not specifically for P. vivax.
Educational context:
Understanding the different uses of antimalarial drugs is crucial for healthcare professionals, especially those working in regions where malaria is prevalent. Recognizing the dual role of erythrocytic schizontocides in both prevention and treatment of malaria is essential for providing effective care to individuals at risk of or affected by malaria. This knowledge is also tested in exams like the NCLEX to ensure healthcare professionals are well-equipped to handle such scenarios in practice.